Abbott Laboratories (ABT) Stock Forecast & Price Target

Compare

8,834 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ABT Analyst Ratings

Strong Buy

17 Buy

2 Hold

0 Sell

Based on 19 analysts giving stock ratings to

Abbott

Laboratories

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ABT Stock 12 Month Forecast

Average Price Target

$147.24

▲(14.23% Upside)

Based on 19 Wall Street analysts offering 12 month price targets for Abbott Laboratories in the last 3 months. The average price target is $147.24 with a high forecast of $162.00 and a low forecast of $136.00. The average price target represents a 14.23% change from the last price of $128.90.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"110":"$110","163":"$163","123.25":"$123.3","136.5":"$136.5","149.75":"$149.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":162,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$162.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":147.24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$147.24</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":136,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$136.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[110,123.25,136.5,149.75,163],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,123.62,126.5723076923077,129.5246153846154,132.47692307692307,135.42923076923077,138.38153846153847,141.33384615384617,144.28615384615384,147.23846153846154,150.19076923076923,153.14307692307693,156.0953846153846,159.0476923076923,{"y":162,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,123.62,125.43692307692308,127.25384615384615,129.07076923076923,130.8876923076923,132.70461538461538,134.52153846153846,136.33846153846156,138.15538461538463,139.9723076923077,141.78923076923078,143.60615384615386,145.42307692307693,{"y":147.24,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,123.62,124.5723076923077,125.52461538461539,126.47692307692309,127.42923076923077,128.38153846153847,129.33384615384617,130.28615384615384,131.23846153846154,132.19076923076923,133.14307692307693,134.0953846153846,135.0476923076923,{"y":136,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":116.39,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":114.64,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.01,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":126.21,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":136.15,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":129.92,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":129.72,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.38,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":135.05,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":126.73,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.88,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.88,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.62,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$162.00

Average Price Target$147.24

Lowest Price Target$136.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Matthew Taylor

Jefferies

$149

Buy

15.59%

Upside

Reiterated

11/21/25

Abbott Laboratories (ABT) Receives a Buy from Jefferies

Danielle Antalffy

UBS

$158

Buy

22.58%

Upside

Reiterated

11/21/25

Abbott Laboratories' Strategic Acquisition of Exact Sciences Bolsters Diagnostics Growth and Expands Cancer Screening Portfolio

Adam Maeder

Piper Sandler

$150

Buy

16.37%

Upside

Reiterated

11/20/25

Piper Sandler Remains a Buy on Abbott Laboratories (ABT)

Matt Miksic

Barclays

$162

Buy

25.68%

Upside

Reiterated

11/20/25

Barclays Sticks to Its Buy Rating for Abbott Laboratories (ABT)

Joanne Wuensch

Citi

$155

Buy

20.25%

Upside

Reiterated

11/20/25

Abbott Laboratories' Strategic Acquisition of Exact Sciences: Enhancing Diagnostics and Driving Long-term Growth

Travis Steed

Bank of America Securities

$150

Buy

16.37%

Upside

Reiterated

11/20/25

Strategic Acquisition and Growth Prospects Drive Buy Rating for Abbott Laboratories

Josh Jennings

TD Cowen

$145

Buy

12.49%

Upside

Reiterated

11/20/25

Abbott Laboratories' Strategic Acquisition of Exact Sciences: A Catalyst for Diagnostics Growth and Market Expansion

Marie Thibault

BTIG

$145

Buy

12.49%

Upside

Reiterated

11/20/25

Strategic Acquisition: Abbott Laboratories' Buy Rating Driven by Exact Sciences DealWe do acknowledge questions about the long-term growth runway for the EXAS Cologuard franchise as blood- based testing has begun to turn heads. If such a deal were undertaken, we are curious to better understand ABT's view of Cologuard's long-term growth outlook (including market expansion capabilities and market share over time), potential for opex synergies, and expectations for the product pipeline, including the exclusive licensing agreement with Freenome (Private).

Bruce Jackson

Benchmark Co.

$145

Buy

12.49%

Upside

Reiterated

11/20/25

Abbott Laboratories' Strategic Acquisition of Exact Sciences: Enhancing Diagnostics Business and Long-term Growth Prospects

Andrew Brackmann

William Blair

―

Buy

―

Reiterated

11/19/25

William Blair Remains a Buy on Abbott Laboratories (ABT)

Robbie Marcus

J.P. Morgan

$140→$145

Buy

12.49%

Upside

Reiterated

11/19/25

Abbott Laboratories' Strategic Acquisition of Exact Sciences Drives Buy Rating

Patrick Wood

Morgan Stanley

$137

Hold

6.28%

Upside

Reiterated

10/17/25

Morgan Stanley Remains a Hold on Abbott Laboratories (ABT)Abbott Laboratories: Equal-Weight; Price Target current 137.00 and previous 137.00; EPS estimates revised from 5.13 to 5.14 and 5.58 to 5.68

Jayson Bedford

Raymond James

$141→$146

Buy

13.27%

Upside

Reiterated

10/16/25

Abbott price target raised to $146 from $141 at Raymond JamesAbbott price target raised to $146 from $141 at Raymond James

Mike Kratky

Leerink Partners

$136

Hold

5.51%

Upside

Reiterated

10/16/25

Analysts Conflicted on These Healthcare Names: Abbott Laboratories (NYSE: ABT), Amgen (NASDAQ: AMGN) and Pharvaris (NASDAQ: PHVS)

Larry Biegelsen

Wells Fargo

$142→$146

Buy

13.27%

Upside

Reiterated

10/16/25

Abbott price target raised to $146 from $142 at Wells FargoAbbott price target raised to $146 from $142 at Wells Fargo

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Matthew Taylor

Jefferies

$149

Buy

15.59%

Upside

Reiterated

11/21/25

Abbott Laboratories (ABT) Receives a Buy from Jefferies

Danielle Antalffy

UBS

$158

Buy

22.58%

Upside

Reiterated

11/21/25

Abbott Laboratories' Strategic Acquisition of Exact Sciences Bolsters Diagnostics Growth and Expands Cancer Screening Portfolio

Adam Maeder

Piper Sandler

$150

Buy

16.37%

Upside

Reiterated

11/20/25

Piper Sandler Remains a Buy on Abbott Laboratories (ABT)

Matt Miksic

Barclays

$162

Buy

25.68%

Upside

Reiterated

11/20/25

Barclays Sticks to Its Buy Rating for Abbott Laboratories (ABT)

Joanne Wuensch

Citi

$155

Buy

20.25%

Upside

Reiterated

11/20/25

Abbott Laboratories' Strategic Acquisition of Exact Sciences: Enhancing Diagnostics and Driving Long-term Growth

Travis Steed

Bank of America Securities

$150

Buy

16.37%

Upside

Reiterated

11/20/25

Strategic Acquisition and Growth Prospects Drive Buy Rating for Abbott Laboratories

Josh Jennings

TD Cowen

$145

Buy

12.49%

Upside

Reiterated

11/20/25

Abbott Laboratories' Strategic Acquisition of Exact Sciences: A Catalyst for Diagnostics Growth and Market Expansion

Marie Thibault

BTIG

$145

Buy

12.49%

Upside

Reiterated

11/20/25

Bruce Jackson

Benchmark Co.

$145

Buy

12.49%

Upside

Reiterated

11/20/25

Abbott Laboratories' Strategic Acquisition of Exact Sciences: Enhancing Diagnostics Business and Long-term Growth Prospects

Andrew Brackmann

William Blair

―

Buy

―

Reiterated

11/19/25

William Blair Remains a Buy on Abbott Laboratories (ABT)

Robbie Marcus

J.P. Morgan

$140→$145

Buy

12.49%

Upside

Reiterated

11/19/25

Abbott Laboratories' Strategic Acquisition of Exact Sciences Drives Buy Rating

Patrick Wood

Morgan Stanley

$137

Hold

6.28%

Upside

Reiterated

10/17/25

Morgan Stanley Remains a Hold on Abbott Laboratories (ABT)Abbott Laboratories: Equal-Weight; Price Target current 137.00 and previous 137.00; EPS estimates revised from 5.13 to 5.14 and 5.58 to 5.68

Jayson Bedford

Raymond James

$141→$146

Buy

13.27%

Upside

Reiterated

10/16/25

Abbott price target raised to $146 from $141 at Raymond JamesAbbott price target raised to $146 from $141 at Raymond James

Mike Kratky

Leerink Partners

$136

Hold

5.51%

Upside

Reiterated

10/16/25

Analysts Conflicted on These Healthcare Names: Abbott Laboratories (NYSE: ABT), Amgen (NASDAQ: AMGN) and Pharvaris (NASDAQ: PHVS)

Larry Biegelsen

Wells Fargo

$142→$146

Buy

13.27%

Upside

Reiterated

10/16/25

Abbott price target raised to $146 from $142 at Wells FargoAbbott price target raised to $146 from $142 at Wells Fargo

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Abbott Laboratories

1 Month

xxx

Success Rate

15/21 ratings generated profit

Average Return

+2.72%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 71.43% of your transactions generating a profit, with an average return of +2.72% per trade.

3 Months

xxx

Success Rate

33/45 ratings generated profit

Average Return

+4.83%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 73.33% of your transactions generating a profit, with an average return of +4.83% per trade.

1 Year

Rick WiseStifel Nicolaus

Success Rate

18/21 ratings generated profit

Average Return

+12.92%

reiterated a buy rating 5 months ago

Copying Rick Wise's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +12.92% per trade.

2 Years

xxx

Success Rate

19/25 ratings generated profit

Average Return

+12.13%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 76.00% of your transactions generating a profit, with an average return of +12.13% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ABT Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ABT has received 41 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. ABT average Analyst price target in the past 3 months is 147.24.

Each month's total comprises the sum of three months' worth of ratings.

ABT Financial Forecast

ABT Earnings Forecast

Next quarter’s earnings estimate for ABT is $1.50 with a range of $1.45 to $1.51. The previous quarter’s EPS was $1.30. ABT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year ABT has Performed in-line its overall industry.

ABT Sales Forecast

Next quarter’s sales forecast for ABT is $11.80B with a range of $11.71B to $11.87B. The previous quarter’s sales results were $11.37B. ABT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year ABT has Performed in-line its overall industry.

ABT Stock Forecast FAQ

What is ABT’s average 12-month price target, according to analysts?

Based on analyst ratings, Abbott Laboratories’s 12-month average price target is 147.24.

What is ABT’s upside potential, based on the analysts’ average price target?

Abbott Laboratories has 14.23% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ABT a Buy, Sell or Hold?

Abbott Laboratories has a consensus rating of Strong Buy which is based on 17 buy ratings, 2 hold ratings and 0 sell ratings.

What is Abbott Laboratories’s price target?

The average price target for Abbott Laboratories is 147.24. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $162.00 ,the lowest forecast is $136.00. The average price target represents 14.23% Increase from the current price of $128.9.

What do analysts say about Abbott Laboratories?

Abbott Laboratories’s analyst rating consensus is a Strong Buy. This is based on the ratings of 19 Wall Streets Analysts.

How can I buy shares of ABT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Abbott Laboratories (ABT) Stock Forecast & Price Target

ABT Analyst Ratings

ABT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Abbott Laboratories

ABT Analyst Recommendation Trends

ABT Financial Forecast

ABT Earnings Forecast

ABT Sales Forecast

ABT Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts